UCLPartners Search Tool – Cholesterol
July 2022

This search identifies all patients who need support in lowering their cholesterol.

Patients are stratified into primary and secondary prevention groups based on their cardiovascular status.

- The secondary prevention group is further stratified into priority groups depending on whether they are on the appropriate statin therapy. Patients not on any statin therapy are in the highest priority group.
- The primary prevention group is also stratified into priority groups based on their QRISK* score and their current statin therapy. Patients not on any statin therapy are in the highest priority group.

This grouping will allow practices to prioritise patients for follow up and to safely phase review appointments over time. An initial contact with patients can be made by a Healthcare Assistant, Social Prescriber or other team member with appropriate training in order to update the relevant clinical information and support education, self-management and lifestyle change aided by digital and other resources. This will help save the clinician time and allow them to be more focused on the clinical interventions, while increasing the quality and quantity of personalised care for the patients.

Note search results may differ from QOF searches because it includes only those patients registered on the day of the search.

Secondary Prevention – Patients with established CVD

Priority One	Priority Two	Priority Three	Priority Four
Not on statin therapy	On suboptimal statin intensity	On suboptimal statin dose	Sub-optimal non-HDL (>2.5mmol/l) levels despite maximal statin

Abbreviations
QOF: Quality Outcomes Framework; CVD: Cardiovascular Disease, IHD: Ischaemic Heart Disease, TIA: Transient Ischaemic Attack, PAD: Peripheral Arterial Disease, CKD: Chronic Kidney Disease

	DENOMINATOR	NUMERATOR
Priority One	AGE ≥18 AND CVD (IHD, STROKE/TIA, PAD)	Not on any statin
Priority Two	AGE ≥18 AND CVD (IHD, STROKE/TIA, PAD)	On simvastatin, pravastatin or fluvastatin
Priority Three	AGE ≥18 AND CVD (IHD, STROKE/TIA, PAD)	Not on atorvastatin 80mg or rosuvastatin 20mg or 40mg (Exclude those in Priority groups 1 and 2)
Priority Four	AGE ≥18 AND CVD (IHD, STROKE/TIA, PAD) AND on atorvastatin 80mg or rosuvastatin 20/40mg	Non-HDL cholesterol >2.5 mmol/l

Primary Prevention

Denominator all adults 18 years and older <u>without CVD</u> (exclude CHD, <u>any</u> stroke / TIA / PAD)

Priority One	Priority Two	Priority Three	Priority Four
Any one of: QRISK* ≥20% CKD 3-5 Type 1 diabetes ≥40 years AND not on a statin	QRISK* 15 to 19% AND Not on a statin	QRISK* 10 to 14% AND Not on a statin	QRISK* ≥10% and **not** on high intensity statin for primary prevention

	DENOMINATOR	NUMERATOR
PRIORITY 1	Last recorded QRISK2/3* = ≥20% OR CKD stage 3-5 OR Type 1 Diabetes age ≥40 years	NOT on statin
PRIORITY 2	Last recorded QRISK2/3* score = 15 to 19%	NOT on statin
PRIORITY 3	Last recorded QRISK2/3* score = 10 to 14%	NOT on statin
PRIORITY 4	All patients with QRISK2/3* of 10% or more AND are on a statin	Not on atorvastatin 20mg, 30mg, 40mg, 60mg, 80mg or rosuvastatin 10mg or 20mg

*QRISK 3 score is recommended to assess CV risk for patients with Severe Mental Illness, Rheumatoid Arthritis, Systemic Lupus Erythematosus, those taking antipsychotics or oral steroids